Articles On Respiri (ASX:RSH)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

The ASX benchmark has ended Wednesday higher after positive inflation data 7 of 11 sectors in the green, IT ahead by circa +2pc Small caps led by Euro Manganese The local market has trimmed the CPI fat of this morning’s gains, after the...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Digital human developer Unith (ASX:UNT) posts 25 per cent lift in revenue for Q1 FY24 At the quarter’s end, the company held $2.7 in cash on hand Unith inked several new contracts over the quarter across the healthcare, e-lottery, and...

  Marjan Mikel – CEO – Respiri (ASX:RSH) offers the only remote patient monitoring program with remote wheeze detection for respiratory disorders as well as a broad number of serious chronic conditions.

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=7D2FBF3D-0297-B05B-8F498AF62BD096F8 –AFT Pharmaceuticals ((AFP)) by Edi...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The benchmark has sagged to -0.24% to close out the week with a world-weary sigh. Falling crude prices hobbled the Energy sector, dragging it 1.93% lower. Small caps winner Rubix Resources is feeling some neighbourly love, thanks to Allk...

Local markets have pedalled furiously since lunch to bring the benchmark to +0.35%. CBA posts record $10.2 billion profit off the back of ever-increasing interest rates. Small capper Perpetual stuns with a 50% spike after buying up land in...

A late surge from InfoTech pushed the benchmark to close at +0.07% InfoTech out front on +1.75%, ahead of Energy and Consumer Discretionary Huge news from Azure helped neighbour Errawarra into top spot for Small Caps   It’s the end of the...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Research reports on ASX-listed companies, to download in full. **** -Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=04E6FD35-F066-D52A-FF94AEB002399CD2 -Carly Holdings ((C...

Whilst the prevalence of Artificial intelligence has boosted the US-tech sector, with the likes of Nvidia and C3.ai seeing their share prices increase by 219% and 265% respectively since the start of the year, Down Under, tech stock valuati...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=628D02C0-B9D8-EA23-2DB35CB4E58A7CBE –AFT Pharmaceuticals ((AFT)) by Edi...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

ShareCafeRespiri (ASX:RSH) – Webinar Presentation Marjan Mikel, CEO and Brian Leedman, Non-Executive Director – Respiri Limited (ASX:RSH) is leading the way in the development of innovative eHealth solutions that aim to improve the managem...

Research reports on ASX-listed companies, to download in full. **** –AFT Pharmaceuticals ((AFP)) – Edison Research: https://www.fnarena.com/index.php/download-article/?n=5CCC26AF-A670-63C8-370E356F819BE3C4 –Barrow Handley Global Share Fund...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

After a feeble start, the benchmark has rallied to close at +0.1% Newcrest and Newmont shake hands on Australia’s biggest goldie takeover Westar Resources shines bright with a 47% price hike   As far as days on the ASX go, that definitely...

Research reports on ASX-listed companies, to download in full. –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=F863639F-EF2C-E5CB-37099553DD439B58 –AFT Pharmaceuticals ((AFP)) by Edison R...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The ASX got an Data Nerd Bailout when the ABS dropped happy-ish CPI data The benchmark recovers from early flesh wounds to end the day flat Ordinary Aussies ‘outraged’ over changes to super that will never, ever affect them The market has...

The ASX climbed 0.4% today after investors threatened it with a stick Mt Monger (ASX:MTM) wins the day by securing funding for it’s Canadian REE play New consumer survey suggests 42% of shoppers might be dumber than previously feared   Au...

Respiri (RSH) becomes the first Australian company to have its medical device receive reimbursement from Centres of Medicare and Medicaid Services in the US The medical device manufacturer can now have its patented wheezo device, used fo...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Respiri (RSH) begins enrolling patients with chronic obstructive pulmonary disease (COPD) in its wheezo remote patient monitoring (RPM) program in Arkansas Respiri will receive recurring revenues per patient per month in addition to devi...

After yesterday’s pre-Chrimbo spend-up, SPI Futures are down 66 points (-0.38%) this morning, threatening to wipe out yesterday’s 41-point gain. That’s on the back of some good/bad, depends-on-your-worldview news out of the US that data con...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

Respiri’s wheezo RPM will be installed in New Mexico, USA Beamtree signs new distributor Bionomics welcomes new CEO   Respiri (ASX:RSH) has secured another primary care practice, Hand Family Healthcare, located in Clovis, New Mexico, USA....

Respiri (RSH) secures an additional primary care practice in New Mexico, US, for its wheezo remote patient monitoring (RPM) programThe company has completed the onboarding of the Hand Family Healthcare practice, which will run a wheezo RPM...

Respiri (RSH) begins onboarding patients in the short wheezo remote patient monitoring (RPM) pilot programRespiri, and partner Access Telehealth, will provide a full solution including the Remotli platform, patient engagement and remote mon...

Respiri (RSH) has secured its first primary care specialty practice in Georgia, USAs such, the company has welcomed its first patients with respiratory disorders to begin the ‘wheezo’ remote patient monitoring programThrough the program, Re...

ASX 200 down -0.4% Small cap index loses -1.7%  Way2VAT: killing it in the VAT space The small caps index has been smashed on Monday as the local Energy and Resources Sectors took fright from what is easily the scariest social unrest acro...

The US FDA conditionally approved Anteris’ DurAVR system Respiri partners with a leading US cardiac centre in Arkansas Emyria accepted into the National Institutes of Health (NIH) program Anteris gets FDA approval Heart specialist Anteri...

The ASX is set to end its four-day winning streak and slip on Monday Wall Street finished mixed after a shortened session China protests have spread across the country The ASX is poised to slip on Monday, ending its four-day winning strea...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Respiri’s (RSH) wheezo device and remote patient monitoring (RPM) solution have been selected by Minnesota Lung Centre (MLC) for a pilot programMLC treats patients with respiratory health needs and has launched this pilot program so it can...

ASX 200 halves gains on the run home  Small cap index closes about 0.7% higher Tinkler takes more Jameson, shares jumps 50%   Up strongly this morning following some epic 90’s style US leads on Friday… …the benchmark ASX200 is giving it...

Respiri (RSH) establishes a Philippine-based Company Centre of Digital Innovation Excellence following an internal review of its global growth requirementsThe Centre of Excellence will undertake the design and development of software underp...

ASX 200 down 1.6% Small caps short 1.3% Real Estate stocks hit ahead of FOMC meet   The benchmark killed Tuesday only to find its very own number was up today. The ASX 200 has spent the session retracing yesterday’s 1.3% gains – driven b...

The ASX 200 is vacillating Small caps are down over 1.3% Demetallica is a great name and it’s up 40% on takeover talk   The benchmark ASX 200 is flat as on Monday. The ASX Emerging Companies (XEC) index has lost 1.3%. REITs and Gold are h...